Highlights Immuron Limited

Equities

IMC

AU000000IMC7

Delayed Australian S.E. Other stock markets 02:22:41 09/05/2024 BST			5-day change	1st Jan Change
0.091 ^AUD	-6.19%		-8.08%	+18.18%

05-03	Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	CI
04-10	Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	04-10	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	03-07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Immuron Limited Clinical Trials Update	12-22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	12-04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	18/10/23	CI
Immuron Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23	CI
Immuron Limited Receives TGA GMP Clearance	09/08/23	CI
Immuron Secures Clearance for Packaging of Immunotherapy Product; Shares Surge 27%	09/08/23	MT
Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study	25/07/23	CI
Immuron Says Ateria Health Introduces Juvia Digestive Formula in Australia	11/07/23	MT
Immuron Limited Approves Proceeding with IMM-529 cGMP Manufacturing and to Proceed with FDA Pre-IND Submission	22/06/23	CI
Immuron Limited Initiates Recruitment of Travelan Clinical Study	30/05/23	CI
PacWest Bancorp, Inflation in Focus Amid Mixed Exchange-Traded Funds, Equity Futures in Premarket Activity	08/05/23	MT
Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation	08/05/23	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2022	28/02/23	CI
Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic	24/01/23	CI
Immuron Obtains European Patent for Drug Composition to Treat Clostridioides Difficile Associated Disease	17/01/23	MT
Immuron Secures US FDA Clearance to Conduct Phase 2 Trial	23/12/22	MT
Immuron Limited Receives FDA Approval for Travelan IND Application	22/12/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immuron Limited

Equities

IMC

AU000000IMC7

Highlights

Filters